InflaRx (NASDAQ:IFRX) Posts Earnings Results, Beats Estimates By $0.08 EPS

InflaRx (NASDAQ:IFRX) issued its quarterly earnings data on Wednesday. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.08, FiscalAI reports.

InflaRx Trading Up 26.9%

Shares of NASDAQ:IFRX traded up $0.53 during trading on Wednesday, reaching $2.50. The company’s stock had a trading volume of 18,208,689 shares, compared to its average volume of 1,612,826. InflaRx has a 12 month low of $0.71 and a 12 month high of $2.86. The firm’s 50 day simple moving average is $1.16 and its two-hundred day simple moving average is $1.12. The stock has a market capitalization of $180.73 million, a PE ratio of -3.29 and a beta of 2.42.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC lifted its holdings in shares of InflaRx by 33.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after acquiring an additional 7,616 shares during the last quarter. HRT Financial LP bought a new position in shares of InflaRx in the 4th quarter valued at about $47,000. Insigneo Advisory Services LLC bought a new position in shares of InflaRx in the 4th quarter valued at about $61,000. Quadrature Capital Ltd bought a new position in shares of InflaRx in the 4th quarter valued at about $104,000. Finally, XTX Topco Ltd bought a new stake in InflaRx in the fourth quarter worth about $135,000. Institutional investors own 42.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Oppenheimer assumed coverage on InflaRx in a research report on Friday, April 24th. They set an “outperform” rating and a $5.00 price objective for the company. Guggenheim restated a “buy” rating and set a $14.00 price objective on shares of InflaRx in a research report on Tuesday, April 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of InflaRx in a research report on Friday, March 27th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $5.80.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.